“We’re not a screening or tools company; we’re a drug discovery company.” Such is the adamant mantra of Kalypsys’ president and CEO John McKearn.

However, the screening technology and tools used by the San Diego-based company for its own drug discovery are apparently viewed as a valuable commodity. In June, the National Institutes of Health’s newly established Chemical Genomics Center selected Kalypsys to provide it with a suite of ultra-high throughput screening technologies in a deal that could be worth $30 million over the next four years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.